DNMT3A and plasma cell myeloma: Gene mutations in ASXL1, DNMT3A, TET2, and TP53 associated with CH were prevalent in peripheral blood monocytes of many AML patients (45%) and less common in lymphoma (19%) and myeloma (20%) patients.